CAV1 and endothelial dysfunction: Inhibiting Cav-1, clathrin, or EEA1 using siRNAs against these components led to the recovery of PM-localized KCa2.3 and KCa3.1 levels, suggesting that siRNAs against these components can be used to treat endothelial dysfunction.